Loading...

Aileron Therapeutics

DB:015
Snowflake Description

Adequate balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
015
DB
$46M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The last earnings update was 23 days ago. More info.


Add to Portfolio Compare Print
  • Aileron Therapeutics has significant price volatility in the past 3 months.
015 Share Price and Events
7 Day Returns
-2.3%
DB:015
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-70.3%
DB:015
-10.2%
DE Biotechs
-6%
DE Market
015 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Aileron Therapeutics (015) -2.3% -14% 39.6% -70.3% - -
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • 015 underperformed the Biotechs industry which returned -10.2% over the past year.
  • 015 underperformed the Market in Germany which returned -6% over the past year.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Aileron Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Aileron Therapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Aileron Therapeutics.

DB:015 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:015
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.448 (1 + (1- 21%) (0%))
1.3
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.3
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.3 * 5.96%)
7.98%

Discounted Cash Flow Calculation for DB:015 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Aileron Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:015 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.98%)
2019 -40.89 Analyst x1 -37.87
2020 24.24 Analyst x1 20.79
2021 115.83 Analyst x1 92.01
2022 178.73 Analyst x1 131.49
2023 270.81 Analyst x1 184.52
2024 320.36 Est @ 18.29% 202.15
2025 361.60 Est @ 12.87% 211.32
2026 394.44 Est @ 9.08% 213.49
2027 419.78 Est @ 6.42% 210.42
2028 438.95 Est @ 4.57% 203.77
Present value of next 10 years cash flows $1,432.09
DB:015 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $438.95 × (1 + 0.23%) ÷ (7.98% – 0.23%)
$5,678.40
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $5,678.40 ÷ (1 + 7.98%)10
$2,636.10
DB:015 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $1,432.09 + $2,636.10
$4,068.19
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $4,068.19 / 26.71
$152.29
DB:015 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:015 represents 0.86549x of NasdaqGM:ALRN
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.86549x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 152.29 x 0.86549
€131.81
Value per share (EUR) From above. €131.81
Current discount Discount to share price of €1.48
= -1 x (€1.48 - €131.81) / €131.81
98.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Aileron Therapeutics is available for.
Intrinsic value
>50%
Share price is €1.48 vs Future cash flow value of €131.81
Current Discount Checks
For Aileron Therapeutics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Aileron Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Aileron Therapeutics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Aileron Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Aileron Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:015 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-2.14
NasdaqGM:ALRN Share Price ** NasdaqGM (2019-04-18) in USD $1.71
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Aileron Therapeutics.

DB:015 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:ALRN Share Price ÷ EPS (both in USD)

= 1.71 ÷ -2.14

-0.8x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Aileron Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Aileron Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Aileron Therapeutics's expected growth come at a high price?
Raw Data
DB:015 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.8x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
11%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Aileron Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Aileron Therapeutics's assets?
Raw Data
DB:015 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $1.33
NasdaqGM:ALRN Share Price * NasdaqGM (2019-04-18) in USD $1.71
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:015 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:ALRN Share Price ÷ Book Value per Share (both in USD)

= 1.71 ÷ 1.33

1.29x

* Primary Listing of Aileron Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Aileron Therapeutics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Aileron Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Aileron Therapeutics has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Aileron Therapeutics expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
11%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Aileron Therapeutics expected to grow at an attractive rate?
  • Unable to compare Aileron Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Aileron Therapeutics's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Aileron Therapeutics's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:015 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:015 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 11%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:015 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:015 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 19 -18 -9 3
2022-12-31 2 -39 -27 3
2021-12-31 0 -29 -29 3
2020-12-31 0 -25 -28 4
2019-12-31 0 -27 -27 4
DB:015 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -28 -32
2018-09-30 -27 -31
2018-06-30 -25 -30
2018-03-31 -22 -26
2017-12-31 -21 -23
2017-09-30 -19 -20
2017-06-30 -18 -18
2017-03-31 -17 -19
2016-12-31 -15 -18
2016-09-30 -14 -17
2016-06-30 -12 -16
2016-03-31 -12 -14

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Aileron Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Aileron Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:015 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Aileron Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:015 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.20 -0.20 -0.20 1.00
2022-12-31 -0.60 -0.60 -0.60 1.00
2021-12-31 -0.75 -0.75 -0.75 1.00
2020-12-31 -0.91 -0.81 -1.04 3.00
2019-12-31 -1.01 -0.91 -1.09 3.00
DB:015 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -2.14
2018-09-30 -2.13
2018-06-30 -2.07
2018-03-31 -2.33
2017-12-31 -3.04
2017-09-30 -5.26
2017-06-30 -41.73
2017-03-31 -43.67
2016-12-31 -42.35
2016-09-30 -40.43
2016-06-30 -38.17
2016-03-31 -33.37

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Aileron Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Aileron Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Aileron Therapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Aileron Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Aileron Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Aileron Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Aileron Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Aileron Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Aileron Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Aileron Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:015 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -31.55 12.35
2018-09-30 -31.38 12.06
2018-06-30 -30.20 12.59
2018-03-31 -25.66 10.04
2017-12-31 -22.65 8.77
2017-09-30 -20.24 7.40
2017-06-30 -18.22 6.42
2017-03-31 -18.83 8.09
2016-12-31 -18.20 7.89
2016-09-30 -17.06 7.82
2016-06-30 -16.04 7.62
2016-03-31 -13.69 5.33
2015-12-31 -12.95 5.06
2015-09-30 -13.00 5.43
2015-06-30 -13.14 5.74
2015-03-31 -14.60 6.22
2014-12-31 -16.07 6.70
2013-12-31 22.35 0.19 6.84

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Aileron Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Aileron Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Aileron Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Aileron Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Aileron Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Aileron Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Aileron Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Aileron Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Aileron Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Aileron Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Aileron Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Aileron Therapeutics Company Filings, last reported 3 months ago.

DB:015 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 19.60 0.00 20.70
2018-09-30 26.03 0.00 27.95
2018-06-30 32.87 0.00 35.79
2018-03-31 40.98 0.00 43.29
2017-12-31 47.80 0.00 50.75
2017-09-30 54.01 0.00 56.87
2017-06-30 9.63 0.00 11.34
2017-03-31 14.28 0.00 15.29
2016-12-31 17.94 0.00 20.72
2016-09-30
2016-06-30
2016-03-31 3.36 0.00 3.77
2015-12-31 3.36 0.00 3.77
2015-09-30 6.48 0.00 7.77
2015-06-30 9.49 0.00 10.56
2015-03-31 9.49 0.00 10.56
2014-12-31 15.57 0.00 16.22
2013-12-31 11.51 0.00 14.07
  • Aileron Therapeutics has no debt.
  • Aileron Therapeutics has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Aileron Therapeutics has less than a year of cash runway based on current free cash flow.
  • Aileron Therapeutics has less than a year of cash runway if free cash flow continues to grow at historical rates of 34.5% each year.
X
Financial health checks
We assess Aileron Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Aileron Therapeutics has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Aileron Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Aileron Therapeutics dividends.
If you bought €2,000 of Aileron Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Aileron Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Aileron Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:015 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:015 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Aileron Therapeutics has not reported any payouts.
  • Unable to verify if Aileron Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Aileron Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Aileron Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Aileron Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Aileron Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Aileron Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Aileron Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Alves Aivado
COMPENSATION $1,758,165
AGE 48
TENURE AS CEO 0.6 years
CEO Bio

Dr. Manuel C. Aivado, also known as Alves, M.D., Ph.D., has been President, Chief Executive Officer and Director of Aileron Therapeutics, Inc. since September 6, 2018. Dr. Aivado served as Chief Medical Officer, Chief Scientific Officer and Senior Vice President of Aileron Therapeutics, Inc. since September 2014 until September 6, 2018. Dr. Aivado served as Vice President of Clinical Development & Pharmacovigilance at Taiho Oncology, Inc. from March 2012 to September 2014. Prior to Taiho, Dr. Aivado held positions of increasing responsibility at GlaxoSmithKline, Inc., including as Senior Medical Director in the Clinical Development group from October 2006 to March 2012, where he was involved in numerous drug programs including ofatumumab (Arzerra(R)), trametinib (Mekinist(R)), pazopanib (Votrient(R)), and eltrombopag (Promacta(R)). Prior to his industry experience, Dr. Aivado practiced clinical medicine in Germany for ten years. During his clinical career, he directed various molecular cancer research projects, which led him to be awarded the prestigious Dr. Mildred Scheel cancer research scholarship award in 2002. Dr. Aivado was previously an Instructor in Medicine at Beth Israel Deaconess Medical Center/Harvard Medical School, where he led the first ever-conducted proteomics research project in Myelodysplastic Syndromes (MDS). During his work in academia and in the pharmaceutical industry, Dr. Aivado's work has culminated in more than 50 peer-reviewed papers, including research articles in Lancet, Nature Genetics and PNAS. Dr. Aivado is a member of the American Society of Hematology and a member of the American Society of Clinical Oncology. He is a German Board-certified physician for Internal Medicine, Hematology and Medical Oncology. Dr. Aivado received an M.D. and Ph.D. from the Medical School of the University of Dusseldorf, in Germany.

CEO Compensation
  • Alves's compensation has increased whilst company is loss making.
  • Alves's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the Aileron Therapeutics management team in years:

0.4
Average Tenure
  • The average tenure for the Aileron Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

Alves Aivado

TITLE
President
COMPENSATION
$2M
AGE
48
TENURE
0.6 yrs

Don Dougherty

TITLE
Senior VP & CFO
COMPENSATION
$2M
AGE
59
TENURE
1.8 yrs

Rick Wanstall

TITLE
Vice President of Finance & Operations

D. Annis

TITLE
Senior Vice President of Research
TENURE
0.4 yrs

Vojo Vukovic

TITLE
Chief Medical Officer
TENURE
0.4 yrs

Kathryn Gregory

TITLE
Chief Business Officer
TENURE
0.1 yrs
Board of Directors Tenure

Average tenure and age of the Aileron Therapeutics board of directors in years:

4.9
Average Tenure
59
Average Age
  • The tenure for the Aileron Therapeutics board of directors is about average.
Board of Directors

Jeff Bailey

TITLE
Chairman of the Board
AGE
55
TENURE
1.1 yrs

Alves Aivado

TITLE
President
COMPENSATION
$2M
AGE
48
TENURE
0.6 yrs

Caleb Winder

TITLE
Director
COMPENSATION
$210K
AGE
46
TENURE
4.3 yrs

Reinhard Ambros

TITLE
Lead Director
COMPENSATION
$193K
AGE
63
TENURE
1.1 yrs

Armen Shanafelt

TITLE
Director
COMPENSATION
$210K
AGE
59
TENURE
5.4 yrs

David Nathan

TITLE
Member of Advisory Board
TENURE
11.5 yrs

Mike Kastan

TITLE
Member of the Scientific Advisory Board
TENURE
11.5 yrs

Loren Walensky

TITLE
Member of Advisory Board

Elliot Ehrich

TITLE
Member of Advisory Board
AGE
59

John McArthur

TITLE
Director
COMPENSATION
$209K
AGE
84
TENURE
8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
15. Mar 19 Sell Novartis Venture Funds Company 13. Mar 19 15. Mar 19 -190,338 €1.87 €-345,724
22. Aug 18 Sell Novartis Venture Funds Company 20. Aug 18 20. Aug 18 -20,388 €2.01 €-41,003
20. Aug 18 Sell Novartis Venture Funds Company 16. Aug 18 17. Aug 18 -17,508 €1.84 €-32,215
16. Aug 18 Sell Novartis Venture Funds Company 14. Aug 18 15. Aug 18 -5,935 €2.00 €-11,592
14. Aug 18 Sell Novartis Venture Funds Company 10. Aug 18 13. Aug 18 -7,215 €2.14 €-15,313
14. Aug 18 Buy John Longenecker Individual 10. Aug 18 10. Aug 18 10,000 €2.15 €21,460
10. Aug 18 Sell Novartis Venture Funds Company 08. Aug 18 09. Aug 18 -1,235 €2.40 €-2,906
08. Aug 18 Sell Novartis Venture Funds Company 06. Aug 18 07. Aug 18 -4,681 €2.61 €-12,122
06. Aug 18 Sell Novartis Venture Funds Company 02. Aug 18 02. Aug 18 -4,702 €2.87 €-13,481
02. Aug 18 Sell Novartis Venture Funds Company 31. Jul 18 01. Aug 18 -12,681 €2.76 €-34,415
31. Jul 18 Sell Novartis Venture Funds Company 27. Jul 18 30. Jul 18 -8,458 €2.89 €-24,218
27. Jul 18 Sell Novartis Venture Funds Company 25. Jul 18 26. Jul 18 -20,397 €3.29 €-65,726
25. Jul 18 Sell Novartis Venture Funds Company 23. Jul 18 24. Jul 18 -31,300 €3.63 €-113,679
18. Jul 18 Sell Novartis Venture Funds Company 16. Jul 18 17. Jul 18 -12,800 €4.41 €-51,689
26. Jun 18 Sell Apple Tree Partners Company 22. Jun 18 26. Jun 18 -106,257 €5.12 €-539,437
22. Jun 18 Sell Apple Tree Partners Company 20. Jun 18 21. Jun 18 -6,647 €4.57 €-30,371
19. Jun 18 Sell Apple Tree Partners Company 18. Jun 18 19. Jun 18 -1,571 €4.62 €-7,254
19. Jun 18 Sell Apple Tree Partners Company 15. Jun 18 15. Jun 18 -7,961 €4.58 €-36,434
14. Jun 18 Sell Apple Tree Partners Company 12. Jun 18 12. Jun 18 -10,843 €4.58 €-49,674
12. Jun 18 Buy Donald Dougherty Individual 08. Jun 18 08. Jun 18 3,000 €4.59 €13,775
11. Jun 18 Sell Apple Tree Partners Company 07. Jun 18 11. Jun 18 -28,162 €4.64 €-128,995
08. Jun 18 Buy Manuel Aivado Individual 06. Jun 18 06. Jun 18 1,000 €4.77 €4,767
04. Jun 18 Buy Donald Dougherty Individual 01. Jun 18 01. Jun 18 2,000 €4.49 €8,979
X
Management checks
We assess Aileron Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Aileron Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company’s lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside. It also develops next generation wild type p53 reactivator that is in preclinical stage for the treatment of solid and liquid tumors. Aileron Therapeutics, Inc. has a collaboration agreement with Dana-Farber/Boston Children’s Cancer and Blood Disorders Center for an open-label, multi-center, pediatric phase 1 clinical trial of ALRN-6924; and Pfizer to evaluate the combination of ALRN-6924 and IBRANCE in MDM2-amplified cancers. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was founded in 2001 and is based in Watertown, Massachusetts.

Details
Name: Aileron Therapeutics, Inc.
015
Exchange: DB
Founded: 2001
$40,618,909
26,713,617
Website: http://www.aileronrx.com
Address: Aileron Therapeutics, Inc.
490 Arsenal Way,
Watertown,
Massachusetts, 02472,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM ALRN Common Stock Nasdaq Global Market US USD 29. Jun 2017
DB 015 Common Stock Deutsche Boerse AG DE EUR 29. Jun 2017
Number of employees
Current staff
Staff numbers
23
Aileron Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 21:59
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/10
Last earnings filing: 2019/03/29
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.